论文部分内容阅读
目的探讨NP方案治疗老年晚期NSCLC的疗效与安全性。方法经病理学或细胞学确诊的ⅢB或Ⅳ期NSCLC患者20例,年龄在60-80岁,ECOG评分为0-2分,均予NVB25-30mg/m2静点第1,8天、 DDP80-100mg/m2第1天,21天为一周期,60-65岁用原量,65-70岁用原量的90%,70-75岁用原量的 80%,75-80岁用原量的70%,二周期后评价疗效及毒副反应,并随访生存期。结果 20例可评价患者中,总有效率达45%,主要毒性反应为骨髓抑制及静脉炎。结论 NP方案治疗老年晚期NSCLC有较好的效果,毒性反应能耐受。
Objective To investigate the efficacy and safety of NP regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Twenty patients with stage ⅢB or Ⅳ NSCLC diagnosed by pathology or cytology were enrolled in this study. The patients were aged 60-80 years with ECOG score of 0-2. All patients were treated with NVB25-30mg / 100mg / m2 on the first day, 21 days for a cycle, 60-65-year-old with the original amount of 65-70 years old with 90% of the original amount, 70-75-year-old with 80% of the original amount, 75-80 years old with the original amount Of the 70%, two cycles after the evaluation of efficacy and toxicity, and follow-up survival. Results 20 evaluable patients, the total effective rate of 45%, the main toxicity was myelosuppression and phlebitis. Conclusion The NP regimen has good effect on the treatment of advanced NSCLC, and the toxic response is tolerable.